anastrozole has been researched along with Cancer of Endometrium in 28 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate whether there may be a role for aromatase inhibitors (AIs) in the treatment of endometrial hyperplasia (EH) and endometrial adenocarcinoma (EA) in postmenopausal women, a retrospective study on the effect of aromatase inhibitors (anastrozole or letrozole) was conducted for 16 patients who were not amenable to surgical treatment." | 7.75 | Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. ( Barker, LC; Brand, IR; Crawford, SM, 2009) |
| "Tamoxifen treatment results in a doubling of the risk of endometrial cancer after 1-2 years of treatment and a quadrupling after 5 years." | 6.72 | The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. ( Bianco, AR; Clack, G; Coibion, M; Duffy, S; Jackson, TL; Lansdown, M; Philips, K; Pollard, S; Wells, M, 2006) |
| "Anastrozole (Arimidex) is an oral nonsteroidal aromatase inhibitor which is active in recurrent breast cancer." | 6.69 | A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. ( Bell, J; Brunetto, VL; Lee, RB; Rose, PG; VanLe, L; Walker, JL, 2000) |
| "Fulvestrant is a new type of oestrogen receptor antagonist with no agonist effects." | 6.43 | Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. ( Abram, P; Vergote, I, 2006) |
| "To investigate whether there may be a role for aromatase inhibitors (AIs) in the treatment of endometrial hyperplasia (EH) and endometrial adenocarcinoma (EA) in postmenopausal women, a retrospective study on the effect of aromatase inhibitors (anastrozole or letrozole) was conducted for 16 patients who were not amenable to surgical treatment." | 3.75 | Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. ( Barker, LC; Brand, IR; Crawford, SM, 2009) |
| "This multicenter, open-label, phase 1/2 randomized clinical trial demonstrated that adding vistusertib to anastrozole improved 8wk-PFR, overall response rate, and PFS for patients with endometrial cancer and had manageable adverse events." | 3.11 | Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial. ( Abdeddaim, C; Arnaud, A; Augereau, P; Bazan, F; Chakiba, C; Chevalier-Place, A; Dalban, C; Diaz, JJ; Fabbro, M; Frenel, JS; Garin, G; Heudel, P; Joly, F; Lancry-Lecomte, L; Marcel, V; Pautier, P; Pérol, D; Ray-Coquard, I; Treilleux, I; You, B, 2022) |
| "Patients with endometrial cancer who consented to participate in the study were randomised to receive anastrozole or placebo for a minimum of 14 days prior to definitive surgery." | 2.78 | Neoadjuvant treatment of endometrial cancer using anastrozole: a randomised pilot study. ( Duffy, SR; Hewitt, MJ; Quinton, ND; Thangavelu, A, 2013) |
| "Tamoxifen treatment results in a doubling of the risk of endometrial cancer after 1-2 years of treatment and a quadrupling after 5 years." | 2.72 | The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. ( Bianco, AR; Clack, G; Coibion, M; Duffy, S; Jackson, TL; Lansdown, M; Philips, K; Pollard, S; Wells, M, 2006) |
| "Anastrozole (Arimidex) is an oral nonsteroidal aromatase inhibitor which is active in recurrent breast cancer." | 2.69 | A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. ( Bell, J; Brunetto, VL; Lee, RB; Rose, PG; VanLe, L; Walker, JL, 2000) |
| "Type I endometrial cancer is a common tumor of the female genital tract." | 2.53 | Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma. ( Babilonti, L; Bogliolo, S; Cassani, C; De Silvestri, A; Dominoni, M; Gaggero, CR; Gardella, B; Musacchi, V; Spinillo, A; Zanellini, F, 2016) |
| "The only alternative to breast cancer screening available in France is surgical prevention by prophylactic mastectomy." | 2.53 | [Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?]. ( Callet, N; Fourme, E; Noguès, C; Reyal, F; Sénéchal, C; Stoppa-Lyonnet, D; This, P, 2016) |
| "Fulvestrant is a new type of oestrogen receptor antagonist with no agonist effects." | 2.43 | Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. ( Abram, P; Vergote, I, 2006) |
| " This study provides RiBi-based markers relevant for a better selection of patients with advanced endometrial carcinoma by predicting the response of endocrine therapy combined with mTOR inhibitor." | 1.91 | Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group. ( Abadie-Lacourtoisie, S; Bazan, F; Chabaud, S; Colombe-Vermorel, A; Coquan, E; Dalban, C; Diaz, JJ; Fabbro, M; Frenel, JS; Garin, G; Heudel, PE; Marcel, V; Martinez, S; Mourksi, NE; Odeyer, L; Pérol, D; Ray-Coquard, I; Simioni, V; Tabone-Eglinger, S; Treilleux, I, 2023) |
| "Anastrozole was administered 1 mg daily orally after performing an accurate clinical and radiological staging." | 1.62 | Palliative treatment of endometrial cancer: what is the role of anastrozole in elderly women? ( Bogliolo, S; Carletti, GV; Cassani, C; De Silvestri, A; Dominoni, M; Gardella, B; Spinillo, A, 2021) |
| "Low-grade endometrial stromal sarcoma is very rare and difficult to diagnose in the early stage." | 1.42 | Long-term survival in low-grade endometrial stromal sarcoma with childbirth and multidisciplinary treatment: a case report. ( Horio, M; Ichihara, S; Inoue, T; Ishihara, Y; Ito, M; Kondo, I; Maeda, O; Matsumura, Y; Moritani, S; Sugiyama, K; Yamamoto, S, 2015) |
| "Anastrozole was effective to recurrent low-grade ESS even after being refractory to progestin therapy." | 1.37 | Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report. ( Ikeda, Y; Kawana, K; Kozuma, S; Nakagawa, S; Oda, K; Shoji, K; Takazawa, Y; Taketani, Y; Yasugi, T, 2011) |
| "We compared the efficacy of endometrial cancer neoadjuvant treatment in 38 patients receiving nonsteroid (letrozol, anastrozol) or steroid (ekzemestan) aromatase inhibitors and 12 patients receiving metformin." | 1.37 | [Effectiveness of aromatase inhibitors in comparison with metformin for neoadjuvant treatment in patients with endometrial cancer]. ( Bershteĭn, LM; Boiarkina, MP; Danilova, MA; Gershfel'd, ÉD; Khadzhimba, AS; Kovalevskiĭ, AIu; Maksimov, SIa; Meshkova, IE; Turkevich, EA, 2011) |
| "Patients with metastatic endometrial carcinoma may respond to hormonal therapy with progestins." | 1.33 | Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex) after prior progestin and anastrozole therapy. ( Hoffman, MA; Khan, A, 2006) |
| "This is the first report of breast carcinoma metastatic to the endometrium in a patient on adjuvant anastrozole therapy." | 1.33 | Lobular carcinoma of the breast metastatic to the uterus in a patient under adjuvant anastrozole therapy. ( Bolat, F; Erkanli, S; Haberal, A; Kayaselcuk, F; Kuscu, E; Sakalli, H, 2006) |
| "Hormonal therapy for endometrial cancer is occasionally warranted in the premenopausal woman who is interested in maintaining fertility." | 1.32 | Anastrozole, an aromatase inhibitor, and medroxyprogesterone acetate therapy in premenopausal obese women with endometrial cancer: a report of two cases successfully treated without hysterectomy. ( Amezcua, C; Bahador, A; Burnett, AF, 2004) |
| "Letrozole was found to be a highly potent inhibitor of tumor proliferation and more effective than tamoxifen." | 1.30 | Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. ( Brodie, A; Liu, Y; Long, B; Lu, Q; Wang, JP; Yue, W, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 12 (42.86) | 29.6817 |
| 2010's | 10 (35.71) | 24.3611 |
| 2020's | 5 (17.86) | 2.80 |
| Authors | Studies |
|---|---|
| Heudel, P | 1 |
| Frenel, JS | 2 |
| Dalban, C | 2 |
| Bazan, F | 2 |
| Joly, F | 1 |
| Arnaud, A | 1 |
| Abdeddaim, C | 1 |
| Chevalier-Place, A | 1 |
| Augereau, P | 1 |
| Pautier, P | 1 |
| Chakiba, C | 1 |
| You, B | 1 |
| Lancry-Lecomte, L | 1 |
| Garin, G | 2 |
| Marcel, V | 2 |
| Diaz, JJ | 2 |
| Treilleux, I | 2 |
| Pérol, D | 2 |
| Fabbro, M | 2 |
| Ray-Coquard, I | 2 |
| Mourksi, NE | 1 |
| Colombe-Vermorel, A | 1 |
| Odeyer, L | 1 |
| Simioni, V | 1 |
| Abadie-Lacourtoisie, S | 1 |
| Coquan, E | 1 |
| Martinez, S | 1 |
| Tabone-Eglinger, S | 1 |
| Chabaud, S | 1 |
| Heudel, PE | 1 |
| Gardella, B | 2 |
| Dominoni, M | 2 |
| Bogliolo, S | 2 |
| Cassani, C | 2 |
| Carletti, GV | 1 |
| De Silvestri, A | 2 |
| Spinillo, A | 2 |
| Friedlander, M | 2 |
| Benson, C | 1 |
| O'Connell, RL | 2 |
| Reed, N | 1 |
| Clamp, A | 2 |
| Lord, R | 2 |
| Millan, D | 2 |
| Nottley, S | 2 |
| Amant, F | 2 |
| Steer, C | 1 |
| Anand, A | 1 |
| Mileshkin, L | 2 |
| Beale, P | 2 |
| Banerjee, S | 1 |
| Bradshaw, N | 1 |
| Kelly, C | 1 |
| Carty, K | 2 |
| Divers, L | 1 |
| Alexander, L | 2 |
| Edmondson, R | 2 |
| Yanase, T | 1 |
| Kikuchi, A | 1 |
| Sasagawa, M | 1 |
| Honma, S | 1 |
| Sjoquist, KM | 1 |
| Andrews, J | 1 |
| Jyothirmayi, R | 1 |
| Bonaventura, T | 1 |
| Goh, J | 1 |
| Hall, M | 1 |
| Green, J | 1 |
| Paul, J | 1 |
| Scurry, J | 1 |
| Boccardo, F | 1 |
| Guglielmini, P | 1 |
| Bordonaro, R | 1 |
| Fini, A | 1 |
| Massidda, B | 1 |
| Porpiglia, M | 1 |
| Roagna, R | 1 |
| Serra, P | 1 |
| Orzalesi, L | 1 |
| Ucci, G | 1 |
| Rubagotti, A | 1 |
| Thangavelu, A | 1 |
| Hewitt, MJ | 1 |
| Quinton, ND | 1 |
| Duffy, SR | 1 |
| Maeda, O | 1 |
| Moritani, S | 1 |
| Ichihara, S | 1 |
| Inoue, T | 1 |
| Ishihara, Y | 1 |
| Yamamoto, S | 1 |
| Ito, M | 1 |
| Matsumura, Y | 1 |
| Sugiyama, K | 1 |
| Horio, M | 1 |
| Kondo, I | 1 |
| Musacchi, V | 1 |
| Zanellini, F | 1 |
| Gaggero, CR | 1 |
| Babilonti, L | 1 |
| Sénéchal, C | 1 |
| Reyal, F | 1 |
| Callet, N | 1 |
| This, P | 1 |
| Noguès, C | 1 |
| Stoppa-Lyonnet, D | 1 |
| Fourme, E | 1 |
| Bellone, S | 1 |
| Shah, HR | 1 |
| McKenney, JK | 1 |
| Stone, PJ | 1 |
| Santin, AD | 1 |
| Barker, LC | 1 |
| Brand, IR | 1 |
| Crawford, SM | 1 |
| Bershteĭn, LM | 2 |
| Danilova, MA | 2 |
| Kovalevskiĭ, AIu | 2 |
| Gershfel'd, ED | 2 |
| Poroshina, TE | 1 |
| Tsyrlina, TE | 1 |
| Meshkova, IE | 2 |
| Turkevich, EA | 2 |
| Maksimov, SIa | 2 |
| Shoji, K | 1 |
| Oda, K | 1 |
| Nakagawa, S | 1 |
| Kawana, K | 1 |
| Yasugi, T | 1 |
| Ikeda, Y | 1 |
| Takazawa, Y | 1 |
| Kozuma, S | 1 |
| Taketani, Y | 1 |
| Lisianskaia, AS | 1 |
| Manikhas, GM | 1 |
| Fadeeva, EP | 1 |
| Fedosenko, KV | 1 |
| Tapil'skaia, NI | 1 |
| Boiarkina, MP | 1 |
| Khadzhimba, AS | 1 |
| Leiser, AL | 1 |
| Hamid, AM | 1 |
| Blanchard, R | 1 |
| Burnett, AF | 1 |
| Bahador, A | 1 |
| Amezcua, C | 1 |
| Hiura, M | 1 |
| Oshita, T | 1 |
| Nogawa, T | 1 |
| Yokoyama, T | 1 |
| Duffy, S | 1 |
| Jackson, TL | 1 |
| Lansdown, M | 1 |
| Philips, K | 1 |
| Wells, M | 1 |
| Pollard, S | 1 |
| Clack, G | 1 |
| Coibion, M | 1 |
| Bianco, AR | 1 |
| Vergote, I | 1 |
| Abram, P | 1 |
| Hoffman, MA | 1 |
| Khan, A | 1 |
| Erkanli, S | 1 |
| Kayaselcuk, F | 1 |
| Kuscu, E | 1 |
| Bolat, F | 1 |
| Sakalli, H | 1 |
| Haberal, A | 1 |
| Alkasi, O | 1 |
| Meinhold-Heerlein, I | 1 |
| Zaki, R | 1 |
| Fasching, P | 1 |
| Maass, N | 1 |
| Jonat, W | 1 |
| Beckmann, MW | 1 |
| Brodie, A | 1 |
| Lu, Q | 1 |
| Liu, Y | 1 |
| Long, B | 1 |
| Wang, JP | 1 |
| Yue, W | 1 |
| Rose, PG | 1 |
| Brunetto, VL | 1 |
| VanLe, L | 1 |
| Bell, J | 1 |
| Walker, JL | 1 |
| Lee, RB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormon[NCT02730923] | Phase 1/Phase 2 | 72 participants (Anticipated) | Interventional | 2016-04-30 | Active, not recruiting | ||
| Gonadotropin-releasing Hormone Agonist Combined With Letrozole Compared With Megestrol Acetate or Medroxyprogesterone Acetate Alone as Fertility-sparing Treatment in Early Endometrial Cancer[NCT05247268] | Phase 2 | 104 participants (Anticipated) | Interventional | 2022-03-11 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for anastrozole and Cancer of Endometrium
| Article | Year |
|---|---|
Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma.
Topics: Adenocarcinoma; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Endometria | 2016 |
[Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Female; | 2016 |
[Postoperative hormone (endocrine) therapy in endometrial carcinoma].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuvant; Drug The | 2004 |
Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
7 trials available for anastrozole and Cancer of Endometrium
| Article | Year |
|---|---|
Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; End | 2022 |
Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903).
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Endometrial Neoplasms; End | 2021 |
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Endometrial Neoplasms; Female; Humans; Immunohistochemi | 2019 |
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; | 2013 |
Neoadjuvant treatment of endometrial cancer using anastrozole: a randomised pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2013 |
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2006 |
A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Carcino | 2000 |
17 other studies available for anastrozole and Cancer of Endometrium
| Article | Year |
|---|---|
Combination Vistusertib and Anastrozole Shows Benefit in Endometrial Cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Benzamides; Breast Neoplasms; Endometrial Neoplasms; F | 2022 |
Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; En | 2023 |
Palliative treatment of endometrial cancer: what is the role of anastrozole in elderly women?
Topics: Aged; Aged, 80 and over; Anastrozole; Endometrial Neoplasms; Female; Humans; Nitriles; Palliative Ca | 2021 |
Two cases of endometrial cancer arising from adenomyosis during aromatase inhibitors therapy after mastectomy.
Topics: Adenocarcinoma; Adenomyosis; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neopla | 2017 |
Long-term survival in low-grade endometrial stromal sarcoma with childbirth and multidisciplinary treatment: a case report.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Endometrial Neoplasms; Female; Humans; | 2015 |
Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole.
Topics: Adenocarcinoma; Anastrozole; Aromatase Inhibitors; Endometrial Neoplasms; Female; Humans; Immunohist | 2008 |
Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.
Topics: Aged; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Carcinoma; Disease Progression; Endo | 2009 |
[Criteria for evaluating the effectiveness of aromatase inhibitors in the neoadjuvant treatment of patients with endometrial carcinoma].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Bi | 2009 |
Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report.
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; En | 2011 |
[Endometrial stromal sarcoma: complete response to therapy with aromatase-inhibitor, anastrozole].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Endometrial Neoplasms; Fem | 2010 |
[Effectiveness of aromatase inhibitors in comparison with metformin for neoadjuvant treatment in patients with endometrial cancer].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Ar | 2011 |
Recurrence of prolactin-producing endometrial stromal sarcoma with sex-cord stromal component treated with progestin and aromatase inhibitor.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2004 |
Anastrozole, an aromatase inhibitor, and medroxyprogesterone acetate therapy in premenopausal obese women with endometrial cancer: a report of two cases successfully treated without hysterectomy.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Endometria | 2004 |
Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex) after prior progestin and anastrozole therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Estradiol; Female; Fulves | 2006 |
Lobular carcinoma of the breast metastatic to the uterus in a patient under adjuvant anastrozole therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duc | 2006 |
Long-term disease-free survival after hormonal therapy of a patient with recurrent low grade endometrial stromal sarcoma: a case report.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease-Free Surviva | 2009 |
Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 1998 |